SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-034942
Filing Date
2024-02-14
Accepted
2024-02-14 06:45:53
Documents
16
Period of Report
2024-02-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d744266d8k.htm   iXBRL 8-K 25357
2 EX-99.1 d744266dex991.htm EX-99.1 99420
6 GRAPHIC g744266dsp1.jpg GRAPHIC 5193
  Complete submission text file 0001193125-24-034942.txt   269160

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sage-20240214.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20240214_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20240214_pre.xml EX-101.PRE 10811
18 EXTRACTED XBRL INSTANCE DOCUMENT d744266d8k_htm.xml XML 3551
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 24632122
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)